Agile Therapeutics Current Ratio 2013-2018 | AGRX

Agile Therapeutics current ratio from 2013 to 2018. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Agile Therapeutics Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2018-09-30 $0.02B $0.01B 2.10
2018-06-30 $0.02B $0.01B 2.19
2018-03-31 $0.03B $0.01B 2.35
2017-12-31 $0.04B $0.01B 2.57
2017-09-30 $0.05B $0.01B 4.10
2017-06-30 $0.03B $0.01B 3.37
2017-03-31 $0.04B $0.01B 3.82
2016-12-31 $0.05B $0.01B 4.70
2016-09-30 $0.06B $0.01B 6.54
2016-06-30 $0.06B $0.01B 6.06
2016-03-31 $0.07B $0.01B 8.15
2015-12-31 $0.04B $0.01B 4.89
2015-09-30 $0.04B $0.01B 5.85
2015-06-30 $0.05B $0.01B 9.02
2015-03-31 $0.05B $0.01B 11.29
2014-12-31 $0.04B $0.01B 4.56
2014-09-30 $0.05B $0.01B 6.50
2014-06-30 $0.05B $0.01B 10.21
2014-03-31 $0.00B $0.00B 0.00
2013-12-31 $0.00B $0.00B 0.00
2013-09-30 $0.00B $0.00B 0.00
2013-06-30 $0.00B $0.00B 0.00
2012-12-31 $0.02B $0.00B 9.65
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.033B $0.000B
Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. It is focused on the development and commercialization of new prescription contraceptive products. The Company's lead product candidate is Twirla (TM), also known as AG200-15, a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Agile Therapeutics, Inc. is headquartered in Princeton, New Jersey.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $46.676B 8.40
Teva Pharmaceutical Industries (TEVA) Israel $17.694B 6.11
Mylan (MYL) United Kingdom $16.304B 6.71
Bausch Health Cos (BHC) Canada $8.412B 5.98
Dr Reddy's Laboratories (RDY) India $5.939B 23.69
Supernus Pharmaceuticals (SUPN) United States $1.968B 18.64
Mallinckrodt Public Limited Company (MNK) United Kingdom $1.768B 2.95
Amphastar Pharmaceuticals (AMPH) United States $1.134B 123.05
Homology Medicines (FIXX) United States $0.930B 0.00
CymaBay Therapeutics (CBAY) United States $0.593B 0.00
Assembly Biosciences (ASMB) United States $0.541B 0.00
Akorn (AKRX) United States $0.507B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.402B 0.00
Voyager Therapeutics (VYGR) United States $0.355B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.307B 0.00
Sol-Gel Technologies (SLGL) Israel $0.122B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.086B 0.00
Teligent (TLGT) United States $0.077B 0.00
Acasti Pharma (ACST) Canada $0.074B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.061B 0.00
Evoke Pharma (EVOK) United States $0.054B 0.00
Aevi Genomic Medicine (GNMX) United States $0.014B 0.00
China Pharma Holdings (CPHI) China $0.012B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.004B 0.00